Skip to main content

dupilumab (Dupixent®)

 

Status: In progress

Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

Medicine details

Medicine name dupilumab (Dupixent®)
Formulation 200 mg solution for injection, 300 mg solution for injection
Reference number 4017
Indication

As above

Company Sanofi-Aventis Ltd
BNF chapter Respiratory system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 14/09/2022
Date of issue TBC
Commercial arrangement PAS
Further information

See NICE TA751: Dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over

Follow AWTTC: